Best Online Weight Loss Programs of 2026
Online weight-loss programs span everything from app-only coaching to full clinical protocols with GLP-1 prescriptions. We scored each on the value of what is included at the entry price, the quality of clinical support, and the breadth of medication options if a patient needs to escalate beyond lifestyle changes.
Rankings combine clinical formulary depth, pricing transparency, and shipping reliability — weighted equally and reviewed quarterly. Read the full methodology →
The Ranking
Personalized clinical weight loss with state-licensed pharmacy fulfillment and an unusually low program entry price.
Flat-rate compounded GLP-1s plus brand-name Wegovy and Zepbound, with all dosages priced the same.
Broad-catalog telehealth covering hair, skin, weight loss, and sexual health, with free shipping and follow-ups bundled in.
Hormone optimisation platform with real biomarker testing and physician-guided protocols, for men and women.
Mainstream telehealth giant with FDA-approved GLP-1s, an insurance concierge, and prepay savings.
Affordable subscription telehealth with one of the largest compounded formularies in the industry.
Full-spectrum GLP-1 program with both compounded and brand-name access plus unlimited provider check-ins.
Flat upfront pricing with the same dose-equal cost across both compounded and brand-name GLP-1s.
Methodology
Programs were judged on entry price, included consultations, formulary depth (oral and injectable), shipping cadence, and provider availability.
The Online Weight-Loss Landscape: Beyond the GLP-1 Headlines
Telehealth weight loss is dominated by GLP-1 marketing, but the category is broader than Wegovy and Zepbound — and for some patients, an older oral medication, a behavioral coaching program, or a combination protocol is a better fit than the headline injectable. Below is how we frame the landscape for readers trying to figure out where they actually fit.
Who Actually Needs a GLP-1 — and Who Doesn't
GLP-1 medications are FDA-approved for chronic weight management in adults with a BMI of 30 or above, or a BMI of 27+ with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia). The trials that established efficacy enrolled this population specifically. For patients with a BMI in the overweight range without comorbidities — say, someone at 28 BMI who wants to lose 15 pounds for a wedding — GLP-1s are technically off-label and the cost-benefit is meaningfully different.
For patients in that lower-acuity range, a structured behavioral coaching program (with or without a non-GLP-1 medication like phentermine or contrave) often produces 5-10% weight loss at much lower cost and with a much shorter side-effect profile. The data is unambiguous that GLP-1s produce more weight loss than other modalities — but 'more weight loss' isn't the only goal, and the price differential is substantial.
Phentermine, Contrave, and Why Older Medications Still Have a Place
Phentermine has been FDA-approved for weight loss since 1959 and remains the most-prescribed weight-loss medication in the United States. It produces an average 5% weight loss over 12 weeks of short-term use and costs $10-30/month. Contrave (naltrexone/bupropion) produces roughly 4-6% weight loss over 12 months and costs $99-$200/month. Topiramate, while not FDA-approved for weight loss alone, is a component of Qsymia and is widely prescribed off-label.
These older medications have known limitations: phentermine is a controlled substance with cardiovascular contraindications; contrave can interact with multiple psychiatric medications; topiramate causes cognitive side effects in a meaningful minority of users. They are not interchangeable with GLP-1s, but they are options — and a serious telehealth weight-loss clinic should at least mention them rather than funnel every patient toward the most expensive injectable.
What Coaching-Plus-Medication Adds
There is a long debate in obesity medicine about whether behavioral support meaningfully adds to medication effects. Recent meta-analyses suggest the answer is yes — patients who pair GLP-1 therapy with structured nutrition and habit support lose roughly 2-4% more body weight than medication-only patients, and they regain less when therapy is paused or discontinued.
Whether that incremental effect is worth the extra $50-150/month a coaching tier costs depends on whether the patient is the kind of person who benefits from accountability infrastructure. Patients who are already disciplined eaters often find structured coaching unnecessary; patients who struggle with emotional eating, irregular meals, or sustained exercise habits typically get real value. It's worth asking yourself which group you're in before paying for the upgrade.
The right starting point for online weight-loss therapy depends on your BMI, your comorbidity profile, your budget, and how you respond to behavior support. The decision helper at the top of this page maps the most common patient profiles to specific clinics, but the broader point is that 'online weight loss' is not synonymous with 'GLP-1 prescription' — it's worth asking whether a different protocol is a better fit before defaulting to the most heavily marketed one.
What the Studies Actually Show
The medication-led programs on this list dispense one of two active ingredients — semaglutide or tirzepatide. The figures below summarise the head-to-head Phase 3 evidence on which the obesity-management approvals rest.
| Endpoint | Finding |
|---|---|
| Mean weight loss (STEP 1, 68 weeks, 2.4 mg)1 | −14.9% body weight vs −2.4% placebo in adults with overweight/obesity without diabetes |
| Cardiovascular outcomes (SELECT, ~40 months)2 | 20% relative risk reduction in major adverse cardiovascular events (MACE) in adults with established CV disease and overweight/obesity |
| GI side effects (FDA prescribing information)3 | Nausea ≥10%, diarrhea ≥10%, vomiting ≥10%, constipation ≥10%; most cases mild–moderate and dose-dependent |
| Mean weight loss (SURMOUNT-1, 72 weeks, 15 mg)6 | −20.9% body weight vs −3.1% placebo in adults with obesity without diabetes |
| Mean weight loss with T2D (SURMOUNT-2, 72 weeks, 15 mg)7 | −14.7% body weight in adults with type 2 diabetes |
| Sleep apnea (SURMOUNT-OSA)8 | Tirzepatide reduced apnea-hypopnea index (AHI) by ~25–29 events/hour vs placebo at 52 weeks; FDA-approved labeling for moderate-to-severe OSA in obesity |
Frequently Asked Questions
Do online weight loss programs prescribe medication?
Most of the programs we list connect patients with licensed clinicians who can prescribe GLP-1 medications, oral options like metformin or phentermine, or hormone-balancing adjuncts when clinically appropriate.
Will insurance cover online weight loss programs?
Insurance coverage is rare for compounded medications and inconsistent for brand-name GLP-1s. Programs like Ro and FuturHealth offer insurance navigation services that can help.
- STEP 1 — NEJM 2021 · Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021;384:989–1002.
- SELECT — NEJM 2023 · Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 2023;389:2221–2232.
- FDA Prescribing Information — Wegovy (semaglutide) · WEGOVY (semaglutide) injection, for subcutaneous use. U.S. Food and Drug Administration prescribing information.
- SUSTAIN program — ADA scientific summary · Aroda VR, Ahmann A, Cariou B, et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 clinical trials. Diabetes Obes Metab 2019;21(7):1601–1613.
- FDA — Compounding and the FDA: Questions and Answers · U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers (last updated 2024).
- SURMOUNT-1 — NEJM 2022 · Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022;387:205–216.
- SURMOUNT-2 — Lancet 2023 · Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2023;402(10402):613–626.
- SURMOUNT-OSA — NEJM 2024 · Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med 2024;391:1193–1205.
- FDA Prescribing Information — Zepbound (tirzepatide) · ZEPBOUND (tirzepatide) injection, for subcutaneous use. U.S. Food and Drug Administration prescribing information.
- SURPASS — program summary · Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med 2021;385:503–515.
- FDA — Compounding and the FDA: Questions and Answers · U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers (last updated 2024).
RxNotebook is an editorial publication. Citations point to peer-reviewed journals, FDA labeling, and clinical society guidelines. We are not affiliated with the studies cited above. This page is for general information and is not medical advice.
Which provider is right for you?
Two questions point you to the right type of program for your weight-loss goals.